Exploring resistance of Plasmodium vivax to antimalarial drugs: A retrospective and prospective study

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1010203

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Although previously considered a 'benign' form of the disease, vivax malaria is increasingly recognised as a cause of complications and even death. Unfortunately, the parasite is developing resistance to conventional drugs. Papua New Guinea was where resistance to chloroquine was first detected and other drugs are following suit. We plan to examine the parasite genes involved in this process, including before and after the introduction of a new strategy in PNG, artemisinin combination therapy.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2013

Funding Scheme: NHMRC Project Grants

Funding Amount: $439,230.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Population, Ecological and Evolutionary Genetics

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

evolution | infectious diseases | malaria drug resistance | malaria therapy | plasmodium | tropical disease | tropical health

Related Links